Covalent hits and where to find them
Covalent hits for drug discovery campaigns are neither fantastic beasts nor mythical creatures, they can be routinely identified through electrophile-first screening campaigns using a suite of different techniques. These include biophysical and biochemical methods, cellular approaches, and DNA-encod...
Main Authors: | Simon C.C. Lucas, J. Henry Blackwell, Sarah H. Hewitt, Hannah Semple, Benjamin C. Whitehurst, Hua Xu |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2024-04-01
|
Series: | SLAS Discovery |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2472555224000042 |
Similar Items
-
Theory and Applications of Covalent Docking in Drug Discovery: Merits and Pitfalls
by: Hezekiel Mathambo Kumalo, et al.
Published: (2015-01-01) -
Bromo-Cyclobutenaminones as New Covalent UDP-<i>N</i>-Acetylglucosamine Enolpyruvyl Transferase (MurA) Inhibitors
by: David J. Hamilton, et al.
Published: (2020-11-01) -
Target-driven machine learning-enabled virtual screening (TAME-VS) platform for early-stage hit identification
by: Yuemin Bian, et al.
Published: (2023-03-01) -
Chagas Disease Drug Discovery in Latin America—A Mini Review of Antiparasitic Agents Explored Between 2010 and 2021
by: Ramon G. de Oliveira, et al.
Published: (2021-10-01) -
Discovery of Monoacylglycerol Lipase (MAGL) Inhibitors Based on a Pharmacophore-Guided Virtual Screening Study
by: Vibhu Jha, et al.
Published: (2020-12-01)